Filing Details
- Accession Number:
- 0001104659-22-129514
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-12-22 16:05:36
- Reporting Period:
- 2022-12-22
- Accepted Time:
- 2022-12-22 16:05:36
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1326190 | Altimmune Inc. | ALT | Pharmaceutical Preparations (2834) | 202726770 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1743611 | Wayne Pisano | C/O Altimmune, Inc., 910 Clopper Road Suite 201S Gaithersburg MD 20878 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.0001 | Acquisiton | 2022-12-22 | 20,000 | $2.60 | 28,498 | No | 4 | M | Direct | |
Common Stock, Par Value $0.0001 | Disposition | 2022-12-22 | 20,000 | $15.01 | 8,498 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.0001 | Stock Options (option to buy) | Disposition | 2022-12-22 | 20,000 | $0.00 | 20,000 | $2.60 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2029-01-02 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.0000 to $15.0900, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The option became vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date.